Smart Medtech Leaders Design with Compliance in Mind: Build Fast; Launch RightExecutive Summary

For MedTech startups, moving fast is essential, but moving forward without a clear regulatory roadmap is a recipe for disaster. Too many companies dive headfirst into product development, only to realize right before their planned launch that they lack the required testing and documentation for regulatory approval. The result is a forced retreat back to the development stage, redesigning the device and wasting immense amounts of time and investor capital.

Performing a comprehensive regulatory assessment at the earliest stages of development is not just a compliance exercise; it is a critical business strategy. By intentionally identifying the Verification and Validation (V&V) requirements, biocompatibility exemptions, sterilization standards, hardware safety protocols, and clinical data needs during the concept phase, MedTech leaders can align their design process with agency expectations. This proactive approach prevents the dreaded cycle of compliance rework and ensures a predictable pathway to market.

1. Strategic Material Selection and Biocompatibility Do not choose raw materials blindly. Opting for materials with a well-known history of use in the medical device industry can save your team months of testing time and significant laboratory costs.

For certain medical devices that only contact intact skin, the FDA offers a "least burdensome" approach outlined in Attachment G of their ISO 10993-1 guidance. This policy allows manufacturers to skip traditional, costly biocompatibility testing if they meet strict criteria, supporting the principles to replace, reduce, and refine animal use in testing.

To leverage this pathway, your device must be fabricated from specific materials with a documented history of safe use, such as synthetic polymers including Polycarbonate (PC), Acrylonitrile-butadiene-styrene (ABS), Polyetheretherketone (PEEK), and Silicone, or natural fabrics like cotton and silk. Instead of testing, manufacturers submit a statement confirming the materials are included in the FDA's list and that the company's Quality Management System (QMS) addresses potential risks through purchasing and manufacturing controls.

However, it is critical to know what is excluded early in the design phase. Novel materials and bulk metals—such as titanium, nitinol, stainless steel, and gold—are strictly excluded from this exemption because they may introduce unique toxicity risks. Understanding these material classifications before finalizing your Bill of Materials (BOM) prevents unexpected testing requirements late in the development cycle.

2. Sterilization Compatibility and Process Validation If your device is intended to be sterile, you must ensure from day one that your chosen raw materials and components are fully compatible with your planned sterilization method. Discovering that a material degrades under radiation or retains toxic gas after the device is built is a costly mistake.

When utilizing Ethylene Oxide (EtO) sterilization, strict compliance with the EN ISO 11135 standard is required. Regulatory reviewers expect a thorough description of the method used to validate the sterilization parameters, explicitly looking for the use of the "half-cycle method" to establish the required Sterility Assurance Level (SAL). Furthermore, because EtO can leave toxic residuals, your submission must state the maximum levels of sterilant residuals remaining on the device and prove they fall below strict safety limits.

Sterility extends beyond the gas or radiation; it relies entirely on the packaging. Validation of the Sterile Barrier System (SBS) must include transit testing under recognized standards (such as ISTA 2A or ASTM D4169) to prove the packaging maintains integrity and product functionality after transportation, environmental simulation, and accelerated aging.

3. Cybersecurity and Software in the eSTAR Era The era of treating software documentation and cybersecurity as post-development afterthoughts is over. With the FDA's eSTAR program now mandatory for 510(k) submissions, the formatting and completeness of your software and security files will be automatically verified.

If your device connects to the internet or contains software, it likely meets the definition of a "cyber device" under Section 524B of the FD&C Act. Modern submissions require comprehensive cybersecurity documentation, including Threat Modeling, Security Architecture Views, and evidence of a Secure Product Development Framework (SPDF) integrated throughout the product lifecycle.

Crucially, the FDA now demands a highly detailed Software Bill of Materials (SBOM). This is not just a list of third-party software; manufacturers must document the "Software Component Support Level" and provide precise "End-of-Support Dates" for every component. For medical devices with long operational lifespans, identifying when a software component will stop receiving security patches is critical for proactive vulnerability planning.

For the software itself, manufacturers must determine their Documentation Level (Basic or Enhanced) based on a preliminary risk assessment. If a software failure could present a probable risk of death or serious injury, Enhanced documentation is required, triggering the need for comprehensive Software Design Specifications (SDS) and detailed unit and integration testing reports.

 4. Verification & Validation for Active Devices: EMC and Electrical Safety For active medical devices, hardware Verification and Validation (V&V) testing is highly scrutinized. It is not enough to simply demonstrate that a device turns on; manufacturers must definitively prove that the device operates safely under extreme real-world conditions without interfering with other equipment.

To satisfy the FDA and EU Notified Bodies, active devices must be tested against the IEC 60601-1 standard for basic electrical safety and IEC 60601-1-2 for Electromagnetic Compatibility (EMC). Passing these tests requires meticulous upfront preparation:

·       Defining Essential Performance: Before sending a device to a testing lab, the manufacturer must explicitly define the device's "Essential Performance" and device-specific pass/fail criteria. These criteria must be quantitative, directly related to the device's intended use, and observable during testing.

·       Operating Modes and Configuration: The EMC report must document all relevant operating modes evaluated during testing (e.g., treatment mode on battery power vs. charging mode via AC adapter) and specify how patient connections were simulated.

·       Wireless Coexistence and Immunity: If the device utilizes wireless technologies (Wi-Fi, Bluetooth, cellular) to support its intended function, these features must be actively transmitting and communicating with other system components during EMC testing. Furthermore, developers must validate the device's immunity to common electromagnetic emitters, such as RFID readers, 5G signals, security systems, and unique medical emitters like MRI or electrosurgical units.

5. Anticipating the Need for Clinical Evidence A flawless bench testing and V&V strategy proves your device operates according to its specifications, but regulators also need proof that the device achieves its intended clinical purpose safely. While many lower-risk devices can be cleared based solely on non-clinical data, a comprehensive regulatory strategy must determine early on whether human clinical studies will be required.

·       Clinical Evaluation vs. Clinical Investigation: Every medical device, regardless of classification, requires a Clinical Evaluation. However, this does not always mean generating new clinical data. Manufacturers can often demonstrate conformity by leveraging existing scientific literature or relying on data from a substantially equivalent predicate device.

·       When Clinical Trials are Mandatory: For high-risk products, such as Class III devices and implantables, the FDA and EU MDR generally require clinical data generated by means of a properly designed, pre-market clinical investigation performed directly on the subject device. Attempting to skip clinical trials for these devices without a highly robust and legally valid justification will result in immediate rejection.

·       Software as a Medical Device (SaMD) and AI Validation: For AI-driven devices and SaMD, clinical validation requires a specific three-pronged approach. Manufacturers must prove a Valid Clinical Association (that the software's output is clinically meaningful for the targeted condition), demonstrate Analytical Validation (that the algorithm correctly processes input data into reliable output), and provide Clinical Validation (that the accurate output actually achieves the intended purpose in the target population).

·       The Article 61(10) Exception: Under the EU MDR, manufacturers of certain Class IIa and Class IIb non-implantable devices may justify an exemption from providing clinical data if they can demonstrate that relying solely on non-clinical bench testing and performance evaluations is sufficient to predict clinical safety. However, this exception requires an air-tight justification based on the device's risk management profile, body interaction, and the complete absence of direct clinical claims.

Conclusion

Understanding these requirements from the beginning ensures that your design process is perfectly aligned with regulatory expectations. By mapping out material exemptions, sterilization standards, rigorous hardware V&V testing, and clinical data requirements during the concept phase, you eliminate the risk of late-stage redesigns. Designing with compliance in mind transforms the regulatory pathway from a potential roadblock into a strategic advantage, allowing your startup to forecast accurate budgets, prove viability to investors, and secure a faster time-to-market.

At BioVision Ltd., we help MedTech founders build comprehensive regulatory roadmaps early in the concept phase, ensuring every design choice supports a smooth, predictable path to clearance.